-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. -
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart FailureMcMurray JJ, Krum H, ATMOSPHERE Committees Investigators.
-
Association of Cardiovascular Disease With Respiratory DiseaseP Carter, J Lagan, C Fortune et al.
-
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionSD Solomon, the PARAGON-HF Investigators and Committees. JohnJV McMurray,
-
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREDewan P, Jackson A, Jhund PS et al.
-
The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and TreatmentBA Borlaug, YNV Reddy.
-
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trialJA Lindenfeld, MR Zile, AS Desai et al.
-
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 InhibitorsS Verma, S Rawat, KL Ho et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
